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OncogeneDuring the last decades a considerable amount of research has been focused on cancer. Recently, tumor cell
metabolism has been considered as a possible target for cancer therapy. It is widely accepted that tumors
display enhanced glycolytic activity and impaired oxidative phosphorylation (Warburg effect). Therefore, it
seems reasonable that disruption of glycolysis might be a promising candidate for speciﬁc anti-cancer
therapy. Nevertheless, the concept of aerobic glycolysis as the paradigm of tumor cell metabolism has been
challenged, as some tumor cells exhibit high rates of oxidative phosphorylation. Mitochondrial physiology in
cancer cells is linked to the Warburg effect. Besides, its central role in apoptosis makes this organelle a
promising “dual hit target” to selectively eliminate tumor cells. From a metabolic point of view, the
fermenting yeast Saccharomyces cerevisiae and tumor cells share several features. In this paper we will
review these common metabolic properties as well as the possible origins of the Crabtree and Warburg
effects. This article is part of a Special Issue entitled: Bioenergetics of Cancer.ergetics of Cancer.
Genetics of the Cell (IBGC) du
, France. Tel.: +33 556999035;
ll rights reserved.© 2010 Elsevier B.V. All rights reserved.1. The hallmarks of cancer cell energy metabolism: The Warburg
effect and the Crabtree effect
In order to proliferate, cells must comply with the energy demand
imposed by vital processes such as macromolecule biosynthesis, DNA
replication, ion gradients generation and cell structure maintenance.
Mitochondria play an important role in energy metabolism as they
synthesize most of the cellular ATP through oxidative phosphoryla-
tion. However, it was suggested that cancer cells suppress mitochon-
drial metabolism [1]. The early discoveries from O. Warburg pointed
out that cancer cells display a decreased respiration along with an
enhanced lactate production, suggesting that they depend mainly on
fermentative metabolism for ATP generation [1]. In spite of the
decrease in energy yield as a consequence of the “glycolytic
phenotype” this seems to allow an increase in cell proliferation rate
and be applicable to other fast growing cells [2].
Because the repression of oxidative metabolism occurs even in the
presence of oxygen, this metabolic phenomenon is known as “aerobic
glycolysis”, also known as the “Warburg effect”. The speciﬁc
advantages that cancer cells acquire by undergoing this metabolic
switch are unknown. Although it is possible that these cells use thismechanism in order to proliferate in hypoxic environments, such as
conditions prevailing within solid tumors [3]. Another hypothesis is
that the down-regulation of oxidative metabolism could help these
cells to escape from apoptosis [4–6]. A correlation between the
glycolytic phenotype and tumor invasiveness has also been suggested
[7].
Nonetheless, there is a considerable body of evidence that
challenges the paradigm of the purely “glycolytic” cancer cell [8]. It
has been demonstrated that some glioma, hepatoma and breast
cancer cell lines possess functional mitochondria and that they obtain
their ATP mainly from oxidative phosphorylation [9–12]. Moreover, it
has been demonstrated that some cancer cells can reversibly switch
between fermentation and oxidative metabolism, depending on the
absence or the presence of glucose and the environmental condi-
tions [13–15]. Interestingly, a recent model proposed that “glycolytic”
cells could establish a metabolic symbiosis with the “oxidative” ones
through lactate shuttling [16]. This points out that the metabolic
plasticity observed in vitro may have an impact on tumor physiology
in vivo. Therefore, it is crucial to understand themechanisms bywhich
cancer cells can reversibly regulate their energy metabolism.
Regarding this, a well-deﬁned feature of some cancer cells is the
glucose-induced suppression of respiration and oxidative phosphor-
ylation [17,18]. This is a short-term and reversible event and is
referred to as the “Crabtree effect”. This reversible shift might
represent an advantage of cancer cells in vivo, as it would allow
them to adapt their metabolism to the rather heterogeneous micro-
environments in malignant solid overgrowths.
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possible target in therapy [10,18] and much of the actual research in
the ﬁeld is being addressed to this particular issue. It is therefore
crucial to clearly understand the long-termmetabolic reprogramming
of cancer cells (the Warburg effect) and the short-term adaptation
mechanisms (the Crabtree effect) as the targeting of both would lead
to much more effective therapeutic strategies.
2. Molecular mechanisms that may give rise to the Warburg effect
It is assumed that theWarburg effect originates from an increase in
glucose uptake and glycolysis and/or a down-regulation of mitochon-
drial metabolism (reviewed in [18]). There is experimental evidence
that ﬁt into each one of these scenarios (Fig. 1). Here we brieﬂy
summarize some of the molecular mechanisms that may give rise to
the aerobic glycolysis phenomenon. Nevertheless, care must be taken
regarding interpretation of the data, as each particular cancer cell
carries its own mutations and there is no unique mechanism that
could explain the Warburg effect.
2.1. Glucose transport and glycolysis
Commonly, the controlling step of a metabolic pathway is the
substrate supply [19]. This has been shown to be the case for some
cancer cell lines [20]. According to this, the overexpression of glucose
transporters has been proposed as one of the main determinants
for the Warburg effect [21]. Results obtained using the positron
emission tomography (PET scan) seem to support this proposal. This
technique is based on the use of glucose derivatives such as 18ﬂuoro-
deoxyglucose as a tracer for imaging its uptake in tissues in vivo [22].
Theoretically, as cancer cells have high glycolytic rates, they will
avidly trap glucose and thus they could be visualized and distin-
guished from normal tissue. FDG-PET has been used for diagnostic
procedures and it has been found to be applicable in a variety ofGlut1, 
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Fig. 1. The mechanisms proposed to explain the aerobic glycolysis (Warburg effect) of cancer
are overexpressed. Hexokinase isoform II (HK II) interacts with mitochondria through the
because the predominance of its L- and P-isoforms. An overexpressed PFKB3 maintains h
pyruvate kinase (PK) regulates the glycolytic ﬂux and promotes metabolite accumulation in o
(LDH) is overexpressed. Pyruvate transport into the mitochondrial matrix through its s
phosphorylation-dependent mechanism mediated by an overexpressed pyruvate dehydrog
The levels of the mitochondrial respiratory complexes I, III and IV are decreased. Mitochoncancers [22]. However, high glucose uptake does not necessarily mean
that mitochondrial metabolism is down-regulated and this must be
taken into account for in vitro studies.
The high afﬁnity glucose transporters (Glut1 and Glut3) are
overexpressed in several cancer cell lines [23]. The inhibition of the
Glut transporters has been used to impair the growth of tumor cells in
vitro [24]. Furthermore, it has been demonstrated that glucose
transport could effectively be the rate-controlling step of glycolysis
in hepatocarcinoma and HeLa cell lines and therefore it may be a
suitable target for pharmacological anti-tumor agents [20].
High glycolytic ﬂuxes may also be explained by the increased
activity of the enzymes participating in the pathway. In this regard, it
has been found that each one of them is overexpressed and/or
deregulated in several cancer cell lines [25]. Although an enhanced
expression cannot be strictly correlated with an increase of the
metabolic ﬂux, some studies have demonstrated that the activity of
each one of the enzymes in the pathway is several-fold increased
compared to their normal counterparts [26]. It is also important to
consider that the contribution to the overall metabolic ﬂux is different
for each enzyme [27]. Consequently, only the stimulation of the steps
that kinetically control the glycolytic ﬂux would have an impact for
the quantitative increase in glycolysis. Hexokinase (HK), phospho-
fructokinase (PFK) and pyruvate kinase (PK) may be the rate-
controlling steps and their regulation and expression patterns change
in some tumors.
Hexokinase II (HKII) is themain isoform expressed in some tumors
[28]. It is found to be associated with the mitochondrial outer
membrane interacting with the voltage-dependent anionic channel
(VDAC) [29]. This localization would allow HKII to immediately use
the ATP generated by oxidative phosphorylation and also it would
help it to overcome the product-mediated inhibition that is normally
observed for this enzyme [29]. In hepatoma and Ehrlich ascites, HKII is
indeed the slowest step in the glycolytic sequence [26,30]. Thus, the
HKII–mitochondria interaction would offer an explanation for thee 1,6-biphosphate 
PK, M2 isoform 
LDH, M 
isoformPC
Pyruvate
Acetyl-CoA
PDH
Succinate Fumarate
x I
SDH
Citrate
Complex
III
PLASMA MEMBRANE
Complex
IV
ATP 
synthase
hondrial 
ose 2,6-biphosphate
Pyruvate
Lactate
Phosphoenolpyruvate
cells. The high-afﬁnity glucose transporters (Glut1 and Glut3) in the plasma membrane
voltage-dependent anionic channel (VDAC). Phosphofructokinase (PFK) is overactive
igher levels of fructose 2,6-biphosphate that further activate PFK. The M2 isoform of
rder to fulﬁll the biosynthetic needs of the cell. TheM-isoform of lactate dehydrogenase
peciﬁc carrier (PC) is decreased. Pyruvate dehydrogenase complex is inhibited in a
enase kinase (PDHK). Mutations in succinate dehydrogenase (SDH) impair its activity.
dria ATP synthase activity is restricted by the overexpression of its inhibitory subunit.
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would not be the case for all tumors as it has been demonstrated that
glucose 6-phosphate effectively inhibits themitochondria-boundHKII
[20,26]. Another drawback of this model is that the high glycolytic ﬂux
would be completely dependent on a functional mitochondrial
metabolism, which is assumed to be downregulated or impaired in
cancer cells (see below).
PFK activity is regulated according to the energy state of the cell,
being inhibited when ATP demand decreases. Some alterations on the
activity of this enzyme have also been reported [31]. For instance, in
leukemia and lymphoma cell lines, the L- and P-isoforms (mainly
expressed in liver and platelets, respectively) are the predominant
forms [32]. Interestingly, the allosteric properties of these isoforms
allow the maximal activity of the enzyme even in low energy demand
conditions, i.e. they respond less effectively to their inhibitors (citrate
and ATP) while they are highly activated by lower concentrations of
fructose 2,6-biphosphate (F26bP) [31,32].
High levels of F26bP are also found on cancer cells [33]. It has been
shown that in malignant cells the levels of this intermediate depend
on PFKB3 (ATP-dependent phosphofructokinase) [34]. This enzyme
belongs to a family of enzymes that have a dual activity: they
phosphorylate fructose 6-phosphate (F6P) to F26bP and they are also
able to revert this by dephosphorylation [34]. PFKB3 is an isoform that
has a low phosphatase activity and is overexpressed in cancer [35].
This may explain the high activity of PFK that has been detected in
some tumors [26].
Pyruvate kinase alterations have also been identiﬁed, as isoform
M2 predominates in some cancer cell lines [35]. PK-M2 activity
depends on its quaternary structure: its tetrameric form ismore active
than the dimer [36]. Some evidences point out that this enzyme is
present in its inactive form in tumors [35]. This is probably mediated
by PK-M2 phosphorylation, elicited by the activation of the tyrosine
kinase signaling triggered by growth factors [37]. The phosphorylated
dimeric form does not allow the binding of the allosteric activator of
the enzyme (fructose 1,6-biphosphate) thereby leading to a lower
activity of PK [38,39]. However, the inhibition of PKM2 seems
contradictory with the high glycolytic ﬂux measured in cancer cells.
Furthermore, an inactive PK would severely impair cell energy
production in the cells that depends mainly on glycolysis for ATP
synthesis. It is proposed that the low activity of PKM2would allow the
accumulation of the glycolysis metabolites that would eventually
serve as precursors for biosynthesis [35].2.2. The pyruvate crossroad
Pyruvate is located at the intersection between two of the main
catabolic pathways of the cell: glycolysis and the Krebs cycle. This
metabolite is transported into the mitochondrial matrix in order to be
converted to acetyl CoA and afterwards enters the Krebs cycle to yield
reducing equivalents that will be used by the respiratory chain to
drive oxidative phosphorylation. Alternatively, pyruvate can remain
in the cytosol and be reduced by lactate dehydrogenase.
To explain the aerobic glycolysis, it has been proposed that
pyruvate could not be efﬁciently metabolized by mitochondria
thereby deviating the metabolic ﬂux into lactate production. Three
events would account for this: a) the restriction of pyruvate transport
into mitochondrial matrix, b) the inhibition of the pyruvate
dehydrogenase complex (PDH) activity, and c) the overactivation of
lactate dehydrogenase.
Pyruvate can enter to mitochondrial matrix through a speciﬁc
carrier located in the inner membrane of this organelle [40]. Pyruvate
transport has been shown to be decreased in mitochondria isolated
from a hepatoma cell line [41,42]. Although this may well explain the
aerobic glycolysis, there is evidence that showed an enhanced
pyruvate uptake and oxidation in a different hepatoma cell line [43].The pyruvate dehydrogenase complex (PDH) catalyzes the
decarboxylation of pyruvate and its condensation with coenzyme A
to produce acetyl-CoA. Its activity is regulated according to the energy
availability in the cell, being inactive when cellular energy supply is
high [44]. PDH activity can also be modulated by reversible
phosphorylation. In this regard, the pyruvate dehydrogenase kinases
(Pdhk) phosphorylate and inactivate the complex while the pyruvate
dehydrogenase phosphatases (PDP) revert this inhibition [44]. A
balance between both processes would deﬁne the activity of PDH and
hence the substrate supply to Krebs cycle. Disruption of the
expression of Pdhk1 decreased lactate production in head and neck
squamous cancer cells suggesting an elimination of the Warburg
effect [45,46]. Moreover, in these cells the expression of Pdhk1 is
mediated by the Hypoxia-Induced transcription Factor 1 (HIF-1)
[45,46], which is also implicated in the overexpression of the
glycolysis enzymes and the glucose transporters in cancer.
An alternative model for the inhibition of pyruvate dehydroge-
nase activity is the production of acetoin, a by-product from the
non-oxidative decarboxylation of pyruvate [47]. This compound
inhibits pyruvate oxidation in isolated mitochondria [48]. Acetoin
is found in signiﬁcant amounts in tumors but not in normal cells,
pointing out a restriction of pyruvate inﬂux into the Krebs cycle
in cancer cells [47]. Nonetheless, the acetoin-mediated inhibition
of PDH could be completely reverted in vitro by ADP and other
respiratory substrates as α-ketoglutarate, malate and glutamate
[48]. Thus, as these other substrates are normally present in the
cell, it is unlikely that the entry of pyruvate to the Krebs cycle be
completely inhibited by acetoin.
Pyruvate is reduced in the cell cytosol by lactate dehydrogenase
in order to keep a constant supply of NAD+ required to drive
glycolysis. This enzyme is also overexpressed in a variety of cancer
cell lines [49] and the disruption of its expression stimulates
respiration and decreases tumor cell viability in hypoxic condi-
tions [50,51]. Lactate dehydrogenase is a homo- or hetero-tetramer
composed of H or M subunits. The latter is the predominant form in
muscle [52]. In several human tumors, an overexpression of the M
subunit was detected [49].
2.3. Krebs cycle and oxidative phosphorylation defects
Defects in the tricarboxylic acid cycle have also been proposed as
high citrate efﬂux is detected on mitochondria isolated from a
hepatoma cell line [53,54]. This seems to correlate with the lack of
state 3 respiration in these mitochondria [53,54]. As citrate is oxidized
by isocitrate dehydrogenase in the cell cytoplasm in order to produce
NADPH, these results could be interpreted as a deviation of carbon
ﬂux towards lipid synthesis as a consequence of an impaired Krebs
cycle. This feature seems to be restricted to this cell line as another
study that used a different hepatoma cell line revealed no citrate
efﬂux [43]. Another impairment of the Krebs cycle may be at the level
of succinate dehydrogenase (SDH), which also participates in the
mitochondrial respiratory chain as the complex II. Mutations on SDH
commonly occur in phaeochromocytomas and paragangliomas [55].
A decrease of ADP translocation to the mitochondrial matrix has
been reported to occur, as well as the inhibition of the ATP synthase
[56,57]. Both events would evidently restrict ATP production in
mitochondria and lead to a diminished respiratory rate and
consequently the cell would have to rely mostly on glycolysis-derived
ATP. Reduced content and/or activity of the respiratory chain
components may occur. There are some reports demonstrating the
down-regulation of complexes I, III and IV [55,58,59]. As mentioned
above, these features could be particular for a speciﬁc cell line and
they could not be extrapolated to other tumors. In fact, other cell lines
possess fully functional oxidative phosphorylation [9–12].
Another interesting feature of cancer cell energy metabolism is
their extensive consumption of glutamine [60]. Glutaminolysis is
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in numerous anabolic pathways (such as nucleic acids) and can be
degraded in the Krebs cycle thereby generating ATP [63,64] through
both substrate level phosphorylation and oxidative phosphorylation.
Glutaminolysis generates i) malate which, through the malic enzyme,
will give rise to NADPH that can be used to fuel lipid biosynthesis; ii)
oxaloacetate, which will generate citrate, which is necessary for lipid
biosynthesis [65]. Consequently, glutaminolysis is an important
pathway mandatory for cancer cell proliferation and could be a
good therapeutic target [66]. It has been shown that glutamine
metabolism can be targeted in humans using the glutamine analogue
DON (6-Diazo-5-oxo-L-norleucine) [67]. However, toxicity can be an
issue in attempts to target glutamine metabolism using DON [68].
Recent studies suggest that the green tea polyphenol (EGCG) could
target glutamine metabolism by inhibiting glutamate dehydrogenase
under low glucose conditions [69].
3. The Crabtree effect and its induction
Some cancer cells, in spite of possessing functional mitochondria,
can switch between glycolytic and oxidative metabolism in a
reversible fashion (the Crabtree effect) [17,18]. Regarding the novel
therapies based on the inhibition of tumor cell energymetabolism, the
sole inhibition of glycolysis would not be sufﬁcient to eliminate all
malignant cells some of them may easily overcome the inhibition of
the fermentative metabolism. This would bring as a consequence the
incomplete elimination of cancer cells and it also would increase the
probability of reoccurrence after treatment. Because of this, it is
important to precisely know the Crabtree effect and its underlying
causes in order to properly target the cancer cells.
The mechanism by which the Crabtree effect is triggered is
unknown. Moreover, it is probable that its induction may be due to a
combination of several factors [70] (Fig. 2). The most accepted
hypothesis is that the glycolysis enzymes (phosphoglycerate kinase
and pyruvate kinase) and mitochondria compete for free cytoplasmicGlucose
Glyceraldehyde 3-phosphate + Pi
1,3-biphosphoglycerate
3-phosphoglycerate
Phosphoenolpyruvate
Fructose 1,6-biphosphate
Pyruvate
ADP
ATP
ADP
ATP
ANT
PiC
CYTOPLASM
GAPDH
PGK
PK
Fig. 2. The mechanisms that could explain the Crabtree effect induction. Glyceraldehyde
compete for the free cytoplasmic phosphate pool (Pi). A similar competition for free ADP o
glycolysis enzymes: Phosphoglycerate kinase (PGK) and pyruvate kinase (PK). Fructose 1,6-b
accumulation in the mitochondrial matrix lead to the inhibition of the ATP synthase. Anoth
membrane.ADP [7,71]. If glycolysis is overactive it could, in theory, override
mitochondria regarding ADP uptake. As the latter is one of the
substrates of oxidative phosphorylation, this would limit one of the
substrates of the ATP synthase and consequently respiration would be
decreased. Nonetheless, it is unlikely that this could occur in vivo as
the Km for the mitochondrial adenine nucleotide translocase (ANT) is
almost 100-times lower than that of the glycolysis enzymes [72]. This
implies that mitochondria would still use the cytosolic ADP even if the
glycolysis enzymes increase their activity.
The Crabtree effect on tumor cells could be eliminated by adding
an excess of phosphate (Pi) in vitro and, because of that, it has been
proposed as the actual trigger of this metabolic phenomenon [73].
This seems in accordance with the dramatic decrease in Pi levels
observed after glucose addition in tumor cells [70]. The thermody-
namic phosphate potential (i.e. [ATP/ADP⋅Pi]), which quantitatively
determines the metabolic ﬂux in the cell [72], may be crucial during
the Crabtree effect [74]. Regarding this, changes in this parameter
have been detected in response to glucose addition to sarcoma ascites
tumor cells [74]. Other studies based on the phosphate potential and
the redox potential ([NAD(P)H/NAD(P)+]) need to be done in order
to conﬁrm the possible implication of the thermodynamic forces.
Cytoplasmic Ca2+ levels could increase depending on physiolog-
ical conditions and in response to speciﬁc stimuli. One study showed
an increased mitochondrial Ca2+ uptake in response to glucose [75].
In these conditions, this cation inhibited the mitochondrial ATP
synthase inducing a decrease of respiration [76]. However, this could
not be taken as a common event of the Crabtree-positive cells as Ca2+
levels were shown to be constant in response to glucose in a different
hepatoma cell line [70].
Mitochondrial outer membrane regulates the access of substrates
to the intermembrane space and thus it could regulate oxidative
phosphorylation [77]. If ADP or the respiratory substrates were kept in
the cytoplasm this would induce a decreased respiratory ﬂux. This
possibility has been overlooked, although it has been suggested
that respiratory substrate availability may decrease in theseVDAC
MITOCHONDRIA
Complex IVComplex III
ATP 
synthaseCa2+
3-phosphate dehydrogenase (GAPDH) and the mitochondrial phosphate carrier (PiC)
ccurs between the mitochondrial adenine nucleotide translocase (ANT) and two of the
iphosphate inhibits the mitochondrial respiratory complexes III and IV. Increased Ca2+
er possible mechanism is a modiﬁed diffusion of ADP through the mitochondrial outer
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cardiomyocytes and HL-1 cardiac cell line, intracellular local restric-
tions of diffusion of adenine nucleotides and metabolic feedback
regulation of respiration via phosphotransfer networks are different,
most probably related to differences in structural organization of
these cells [79]. Moreover, contrary to cardiomyocytes where
mitochondria and CaMgATPases are organized into tight complexes
which ensure effective energy transfer and feedback signaling
between these structures via specialized pathways mediated by CK
and AK isoforms and direct adenine nucleotide channeling, these
complexes do not exist in HL-1 cells due to less organized energy
metabolism [80]. In such cells the permeability of the outer
membrane for ADP and other substrates is increased and the
mitochondrial compartment is very dynamic leading to an increase
in ATP consumption [81,82].
One mechanism that links glycolysis acceleration to the inhibition
of respiration is fructose 1,6-biphosphate (F16bP) [83]. At physiolog-
ical levels, F16bP induce a decrease on the activity of mitochondrial
complexes III and IV [83]. An important ﬁnding was that the Crabtree
effect could be induced onmitochondria isolated from normal rat liver
by incubating them in the presence of F16bP concentrations similar to
those measured in hepatoma cells [83]. This demonstrates that the
impairment of the mitochondrial oxidative metabolism is not a
requisite for the Crabtree effect induction and may explain its
reversible nature.Glucose
Glucose 6-
phosphate
Overxpressed. Bound 
to mitochondria. 
Insensitive to G6P-
mediated inhibition
HK
Fructose 6-phosphate
Fructose 1,6-biphosphate
Overexpressed and 
overactive. High levels 
of  one  of its allosteric 
activators (F26bP)
PFK
Pyruvate
Lactate
Overexpressed and 
overactiveLDH
PDH
Acetyl-CoA
Inhibited by an 
overexpressed PDHK
Citrate
Succinate
Fumarate
SDH
Mutations in subunits 
D,B, and C
Respiratory 
chain:
Krebs 
cycle Complex IV
ATP synthase 
Decreased expression
Increased expression 
of its inhibitory subunit
Cancer cells
Mitochondrial 
matrix
Cytoplasm
Fig. 3. Metabolic similarities between cancer cells and yeast. Hexokinase (HK) isof
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inhibited through phosphorylation by an overexpressed pyruvate dehydrogenase kinase (PD
and its expression is down-regulated in yeast. In both cases, a decreased expression of mit4. Cancer cell and yeast metabolism: Metabolic similarities
The budding yeast Saccharomyces cerevisiae possesses the ability to
adapt its metabolism to the environmental conditions. When glucose
supply is high, the yeast use fermentation as its main metabolic
pathway and when this carbon source is scarce it can switch to
oxidative metabolism. This is regulated by short- and long-term
events [84].
Regarding energy metabolism, there are similarities between the
glucose-induced repression of oxidative metabolism of yeast and the
“aerobic glycolysis” of tumor cells (Fig. 3). In both cell types, the
downregulation of oxidative metabolism is observed along with an
enhanced fermentation despite the presence of oxygen (reviewed
in [18]). Moreover, S. cerevisiae is a Crabtree-positive cell [85]. This
points out S. cerevisiae as an amenable metabolic model for the
screening of metabolism-targeted drugs employed for anti-tumor
therapy [18].
Yeast shares with cancer cells the metabolic features that are
identiﬁed as the underlying causes of the Warburg effect (see above)
[18]. For instance, as cancer cells, fermenting yeast over-express all
glycolysis enzymes in response to glucose [86,87]. The activity and/or
expression pattern of the glycolysis key enzymes (hexokinase,
phosphofructokinase and pyruvate kinase) are also modiﬁed in
yeast. During growth on glucose, only hexokinase II is expressed
[87,88]. The latter is a high afﬁnity isoform that is insensitive toGlucose
Glucose 6-
phosphate
Overexpressed. 
Insensitive to G6P-
mediated inhibition
HK
Fructose 6-phosphate
Fructose 1,6-biphosphate
Overactive. High levels 
of  one of its allosteric 
activators (F26bP)
PFK
Pyruvate
Acetaldehyde
Overexpressed and
overactivePDC
PDH
Acetyl-CoA
Decreased expression 
of the E3 subunit. 
Inhibited by an 
overexpressed PDHK
Citrate
Succinate
Fumarate
SDH
Decreased expression
Krebs 
cycle
Respiratory 
chain:
Complex IV
ATP synthase 
Decreased expression
Decreased levels
Yeast
Mitochondrial
matrix
Cytoplasm
orms insensitive to glucose 6-phosphate-mediated inhibition are overexpressed.
fructose 2,6-biphosphate (F26bP). The enzymes that metabolize pyruvate in the cell
d pyruvate decarboxylase in yeast (PDC). Pyruvate dehydrogenase complex (PDH) is
HK). Succinate dehydrogenase (SDH) has mutations in different subunits in cancer cells
ochondrial complex IV is observed as well as a down-regulation of the ATP synthase.
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changes in the expression of phosphofructokinase [90], it is highly
active because of the increased levels of its allosteric activator
(fructose 2,6-biphosphate) [91]. In fermentative conditions a pyru-
vate kinase isoform (Pyk1) is expressed, that responds more
effectively to the allosteric activation mediated by fructose 1,6-
biphosphate [92].
As in tumors, the regulation at the pyruvate crossroad level was
demonstrated to occur in yeast. During fermentation, the entry of
pyruvate to the Krebs cycle seems to be limited by the down-
regulation of its oxidation while its cytoplasmic metabolism is highly
active (see below).
S. cerevisiae also has a pyruvate transport that translocates it into the
mitochondrial matrix [93]. As for the mammalian homologue, little is
knownabout the regulation of this carrier and thegene sequence coding
for the yeast homologue has just recently been identiﬁed [94].
The yeast also expresses homologues of the mammalian pyruvate
dehydrogenase kinase (Pdhk) and the respective phosphatases (Pdp)
(see above) [95,96]. The activity of the yeast pyruvate dehydrogenase
is restricted by the phosphorylation of the enzyme [97]. The depho-
sphorylated form has been detected in yeast growing on non-
fermentable carbon sources, i.e. when these cells obtain their energy
mainly through oxidative metabolism [95]. Pyruvate dehydrogenase
complex is also submitted to transcriptional regulation, as the
expression of its subunit E3 (lipoamide dehydrogenase) is decreased
during fermentation [98].
Lactate dehydrogenase is also present in yeast: two isoforms are
located in the mitochondrial inner membrane [99,100]. The mitochon-
drial forms irreversibly oxidize lactate to pyruvate and participate in the
respiratory chain [99,101] and the role of the cytoplasmic isoform is still
unknown. In yeast, the reduction of pyruvate metabolism in cytosol
depends mainly on pyruvate decarboxylase (Pdc) [102]. This enzyme
produces acetaldehyde that is either oxidized in mitochondrial matrix
[103] or reduced to ethanol by alcohol dehydrogenase (Adh) in a
reaction that reoxidize the cytoplasmic NADH [104]. Even though the
cytoplasmic pyruvate metabolism is not strictly the same as that of
tumor cells, an increased ﬂow through this pathway inhibits the
substrate supply to oxidative metabolism, just as seen with the
increased activity of lactate dehydrogenase in cancer cells. According
to this, during the onset of fermentation the activation of Pdc is
concomitant with a decrease in respiration [85].
Krebs cycle down-regulation has also been identiﬁed in ferment-
ing yeast. In these conditions the enzymatic activities of aconitase,
isocitrate dehydrogenase and malate dehydrogenase are decreased
[105]. The activity of the mitochondrial respiratory complexes II and
IV is also lower in fermentation. This may originate by negative
regulation at the transcriptional level [86,105].
As mentioned above, S. cerevisiae is a Crabtree-positive: after
glucose addition, respiration is inhibited [83]. The same mechanisms
that could explain the Crabtree effect induction in tumor cells (see
above) may equally apply to the yeast model: limitations in ADP and
Pi levels [106], Ca2+-induced decrease in respiration [107], reduced
permeability of themitochondrial outermembrane [108] and fructose
1,6-biphosphate mediated inhibition of the respiratory chain [83].
There are yeasts other than S. cerevisiae that are classiﬁed as Crabtree-
negative, such as Candida utilis and Kluyveromyces lactis [85]. The
characterization of the differences between both yeast types may
provide some insight into the precise mechanisms by which the
Crabtree effect is induced. In this regard, it has been demonstrated
that C. utilis is insensitive to the effect exerted by fructose 1,6-
biphosphate [83]. This indicates that this mechanism is a particular
feature of the Crabtree-positive cells.
Although it may be argued that fermenting yeast lack the genetic
defects identiﬁed in cancer cells, S. cerevisiae possesses homologues of
cancer-related genes (such as p53, BRCA1, BRCA2, Cyclin D and Ras)
[109]. An interesting approach would be to introduce mutations inthese genes and use this “tumorized yeasts” as a model for anti-cancer
drug screening and for metabolism studies in order to determine how
each one of thesemutationswould contribute to theWarburg effect in
cancer.
5. Metabolism regulation by oncogenes-homologues in yeast
A cell must generate enough energy and acquire or synthesize
biomolecules at a sufﬁcient rate to meet proliferation demands.
Cancer is essentially a disease in which cells have lost their usual
checks on cell proliferation. Consequently, tumor cells often display
fundamental changes in pathways of energy metabolism and nutrient
uptake [110]. Furthermore, several of the mutations that lead to
cancer also drive the altered metabolism of tumor cells [111]. This
fundamental metabolic switch may confer a selective growth
advantage and/or resistance to apoptosis to allow cancer cells to
maintain mitochondrial bioenergetics and integrity during cell
growth and proliferation. How oncogene and tumors suppressor
networks inﬂuence cellular metabolism and bioenergetics to support
growth and proliferation in mammalian cells has been extensively
reviewed [112]. We will focus here on some of the yeast homologues
of cancer-related genes and their inﬂuence on yeast cell metabolism
and proliferation.
5.1. The Ras oncogene
The Ras subfamily is a protein subfamily of small GTPases involved
in cellular signal transduction, and is also used to designate gene
subfamily of the genes encoding those proteins. Activation of Ras
signaling causes cell growth, differentiation and survival. Ras is the
prototypical member of the Ras superfamily of proteins which are all
related in structure and regulate diverse cell behaviors. In yeast,
the Ras proteins (Ras1 and Ras2) regulate the cAMP/PKA-signaling
pathway which is involved in many physiological adaptations of cells
in response to environmental changes. This includes the diauxic shift,
responses to nutrient starvation, oxidative stress, and heat shock
[113–118]. In the yeast Ras signaling cascade, CDC25 catalyzes the
conversion of GDP-Ras1 and GDP-Ras2 to GTP-Ras1 and GTP-Ras2,
which are the activators of CYR1, the adenylate cyclase [119] which
catalyzes cAMP synthesis. The cAMP intracellular concentration thus
depends on the respective activities of CYR1 and the phosphodies-
terases PDE1 and PDE2. High cAMP concentrations promote the
dissociation of the regulatory subunit (BCY1) [120] from the catalytic
subunits (TPK1, TPK2, and TPK3) [121], thus activating the catalytic
subunits of protein kinase A (PKA), which phosphorylates a variety of
substrates.
The homologue of the RasV12 mammalian oncogene is the RasV19
protein in yeast. The yeast strain carrying this mutation has been
extensively studied and harbors profound modiﬁcation in its energy
metabolism. Indeed, the Ras2V19 strain is affected in its ability to
store glycogen [122] and presents a hyperinvasive growth phenotype.
Further, mitochondrial metabolism is profoundly modiﬁed and
quantitative measurements show that there is an increase in
mitochondrial amount in the cells carrying the Ras2V19 allele. Both
cellular respiratory rate andmitochondrial cytochromes are increased
(×2) [123]. This phenomenon leads to uncoupling between biomass
synthesis and catabolism and generates a decrease in the enthalpy
growth yield [124]. This study showed that mitochondria by
themselves are a major heat dissipative system in a fully aerobic
metabolism and that a subtle adaptation of the amount of mitochon-
dria to the growth rate is necessary to maintain the enthalpy growth
yield. Further studies with yeast mutants of the Ras/cAMP cascade
have shown that this pathway is a major regulator of mitochondrial
energy metabolism [123–128] in such a way that an overactivation of
this cascade induces an increase in this metabolism whereas an
underactivation of this cascade induces a decrease in this metabolism.
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increases mitochondrial metabolism [129], further strengthening the
fact that there is strong similarities between the regulation of yeast
and mammalian cells energy metabolism by oncogene/oncogene
homologues.
5.2. Sch9, the yeast homologue of Akt
Growth factor-independent activation of the PI3K/Akt (a known
oncogene) pathway drives changes in cellular metabolism to promote
cancer cell growth and proliferation [112]. The SCH9 gene of the yeast
S. cerevisiae encodes a serine–threonine protein kinasewith a catalytic
domain very similar to that of human Akt1 [130]. There are several
lines of evidence that Sch9p plays an important role in glucose
signaling in the budding yeast. Early work showed parallelism and
complementarity of SCH9 signaling with the cyclic AMP-dependent
protein kinase (PKA) pathway, which signals hexose abundance [131–
134]. It was also shown that Sch9p integrates nutrient signals with cell
size regulation. In fact, theΔsch9mutationwas one of themost potent
modiﬁers of cell size identiﬁed in a genome-wide screen for pathways
coupling cell growth and division in yeast [135]. Sch9p is an activator
of ribosomal protein and ribosomal biogenesis regulons and is
required for carbon source modulation of cell size [136]. Furthermore,
it was recently shown that the Δsch9 mutation upregulates electron
transport chain gene expression and that this is associated with an
increase in mitochondrial respiration [137], further strengthening the
fact that yeast homologues of oncogene play a role in the regulation of
cell metabolism.
It has recently been shown that yeast Sch9 is a central component
of a network that controls a common set of genes implicated in a
metabolic switch from the TCA cycle and respiration to glycolysis and
glycerol biosynthesis. During chronological survival, mutants lacking
SCH9 depleted extracellular ethanol and reduced stored lipids, but
synthesized and released glycerol. Deletion of the glycerol biosyn-
thesis genes GPD1, GPD2, or RHR2, among the most up-regulated in
long-lived Δsch9, Δtor1, and Δras2 mutants, was sufﬁcient to reverse
chronological life span extension in Δsch9 mutants, suggesting that
glycerol production, in addition to the regulation of stress resistance
systems, optimizes life span extension [138].
5.2.1. Conclusion
The emergence of metabolic enzymes as important regulator of
cancer cell growth suggests that metabolic control is a key element of
tumor progression. Understanding the pathways that regulate cancer
cell metabolism may lead to greater understanding of cancer cell
development and progression, and has the potential to open a new
vista of metabolic therapy for cancer treatment. As shown in the last
paragraph of this review, there are strong similarities between
mammalian and yeast cell metabolism regulation by oncogenes/
oncogenes homologues. An interesting approach would be to use
“tumorized yeasts” as a model for anti-cancer drug screening and for
metabolism studies in order to determine how each one of these
mutations would contribute to the profound metabolic alterations in
cancer.
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